RxDoctor Payments Data

Ebony Elam, NP

Psychiatric/Mental Health · Lyndhurst, OHNPI 1568582724

Payments from drug & device makers

$613in general payments, 2019–2025

Across 19 payments — averaging $32.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$203
  • Johnson & Johnson$187
  • AbbVie$47
  • Alkermes, Inc.$33
  • Acadia Pharmaceuticals Inc$33
  • Axsome Therapeutics, Inc.$31
  • plus $79 from 4 others

What the payments were for

  • Food & beverage$613100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$613 in reported general payments places this provider in the 45th percentile of 1,808 psychiatric/mental health providers in Ohio.

See all psychiatric/mental health providers in Ohio

Medicare billing

Part B allowed, 2024
$4,213
Medicare patients
36
Services billed
45

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate16$111,478
Invega SustennaPaliperidone Palmitate15$42,375
RexultiBrexpiprazole25$40,742
Risperdal ConstaRisperidone Microspheres26$30,285
AristadaAripiprazole Lauroxil12$26,023
Paliperidone ErPaliperidone97$22,432
VraylarCariprazine Hcl13$16,815
TrintellixVortioxetine Hydrobromide32$15,451
Aripiprazole172$13,078
FetzimaLevomilnacipran Hcl13$7,211
Divalproex Sodium62$6,109
Desvenlafaxine Succinate ErDesvenlafaxine Succinate34$5,966
Lurasidone Hcl37$5,708
Buspirone Hcl256$5,348
Clozapine102$5,247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$187$72,66041 claims
Otsuka America Pharmaceutical, Inc.Rexulti$26$40,74225 claims
Alkermes, Inc.Aristada$33$26,02312 claims
AbbVieVraylar, Fetzima$47$24,02626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,808 psychiatric/mental health providers in Ohio.

Other psychiatric/mental health in Lyndhurst

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →